We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Pedro Coelho, Founder and CEO at Biorce! In this episode, I sit down with Coelho to explore how his team went from flagging protocol mistakes to building AI that fixes them — and in doing so, became the first company to submit an AI-generated protocol to the FDA. Coehlo breaks down how Biorce can generate a best-in-class clinical trial protocol in under 5 minutes, why risk-based remote monitoring is the industry’s biggest anti-pattern, and what a “one-click clinical trial” could look like by the end of 2026.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn.

If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes.

Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Eddy Ben-Ami, Founder and CEO at NeuraLight! NeuraLight is tackling one of neurology’s biggest problems: how crudely we measure disease progression in conditions like Parkinson’s, MS, ALS, and Huntington’s. Despite MRI and gene sequencing, the current “gold standard” is pushing patients to test balance, or asking caregivers how hard it is to adjust clothes in bed.

Ben-Ami explains how NeuraLight replaces this with a 10‑minute, tablet-based eye-movement test using a standard camera. By leveraging decades of visual-system research (largely from primate studies), they extract functional biomarkers tied to specific neural pathways and brain regions. The result: objective, quantitative measures of brain function that are highly sensitive to change over time.

Over the past four years, NeuraLight has run large longitudinal studies on thousands of patients across multiple neurodegenerative diseases. In Parkinson’s, they’ve shown their metrics are 10x more sensitive to change than the existing clinical gold standard, with results being presented at ADPD in Copenhagen alongside the inventors of that standard.

Commercially, NeuraLight is already being paid as a per-test diagnostic in five pharma drug trials (Phase 1 and 2), where their measures serve as secondary/exploratory endpoints. Their moat is a growing, hard-to-replicate dataset linking eye movements to rich clinical data. 

Looking ahead to 2026, they’re focused on successful readouts from ongoing trials, expanding into psychiatry, and bringing their technology into preventative-care platforms so even healthy people can track brain function—before catastrophe strikes.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn.

If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes.

Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Alison Holland, Chief Customer Officer at Medable! In this episode, I talk with Holland about how her journey from London nurse to Covance veteran to digital trial leader shapes Medable’s strategy.

Holland started at the bedside and then spent nearly 20 years at a major CRO – Covance. She learned where trials really break: overloaded sites, fragmented systems, and patients battling logistics instead of disease. Medable’s answer is a reusable SaaS platform plus tightly scoped AI agents—first for CRAs, then for TMF, and next for sites—that automate the manual, low‑value work while keeping humans firmly in the loop.

She walks through concrete wins: PRO compliance jumping from ~75% to 95%, 20% more primary endpoint data, and up to 100 hours saved in study startup by configuring from therapeutic‑area libraries instead of rebuilding from scratch.

Holland’s chosen industry anti‑pattern is “change fatigue”: an exhausted ecosystem that no longer believes transformation will stick. Her counter is precision use cases that deliver undeniable value, build momentum, and make it possible to say, credibly, “Yes, we can” this time.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn.

If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes.

Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Kim Boericke, the new CEO at Veristat! In this episode, I sit down with Kim to explore what it really takes to build and lead a durable CRO in a rapidly shifting life sciences landscape. We discuss Kim’s leadership journey, how value is created and captured in services-heavy businesses, and what Veristat is prioritizing for customers over the next 12 months. The conversation then goes deeper into the idea of moats—what makes a CRO genuinely hard to copy, what compounds over time, and how strategic decisions today shape defensibility five years out.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn.

If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes.

Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Josh Haimson, Co-Founder and CEO at Inductive Bio! Josh Haimson joins me to talk about how their virtual lab can run millions of in silico experiments to predict how molecules will behave in the body and surface the strongest hypotheses to test in the wet lab.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn.

If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes.

Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Olympian-turned-founder Simon Arkell joins Life Sciences Today to explain how Ryght.ai is reinventing clinical trial site selection. He unpacks digital twins for 100,000+ sites, AI agents, and why EMR-centric models are an anti-pattern—showing how sponsors can slash enrollment risk, save hundreds of millions, and scale globally.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn.

If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes.

Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Asta Ratkeviciene, Co‑Founder and CEO at MedSyntra. In this episode of Life Sciences Today, I talk with Ratkeviciene about building a global, ethically sourced medical imaging data infrastructure across radiology, pathology, oncology, and women’s healthcare. Ratkeviciene explains how MedSyntra aggregates and de-identifies millions of imaging studies, provides a highly curated data marketplace and platform for institutions that require data sovereignty, and partners with clinical experts for annotation and external teams for model development. They discuss why imaging is the core focus, how population differences can degrade AI performance across geographies, MedSyntra’s evolving business model, and the biggest anti‑patterns Ratkeviciene sees in the medical AI ecosystem today.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn.

If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes.

Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Erez Lampert, Founder and CEO at PathKeeper Surgical! I talk with Lampert about his journey from Israel’s aerospace industry and Invisalign’s Itero scanner to founding PathKeeper in 2018–2019. We dig into the core problem in spine surgery—surgeons “flying blind” between low‑cost, high‑radiation fluoroscopy and ultra‑expensive robotics—and how PathKeeper offers a third way using optical 3D imaging and AI. Erez explains their dual business model (capital + disposables, plus a “razor blade” model via implant partners in a $10B US spine market), and how strategic deals with High Ridge Medical (Zimmer Biomet spine) and Vizient unlock scalable US commercialization without a 50‑person direct sales team. The conversation challenges the myth that Israelis don’t know how to sell in the US, reframing success as understanding gatekeepers, GPOs, and distribution science rather than just raising $50M and hiring a big sales force.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn.

If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes.

Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Kiril Pevsner, Co-Founder and CTO at Protai. We kick this episode off by discussing how Pevsner creates and captures value with pharma. Then we talk about where AI meaningfully shapes decisions in the early discovery and preclinical work. Next, we take a look at where pharma teams hesitate to act on AI-driven insights, even when the science looks strong. We conclude this episode with Pevsner sharing where he doesn’t think AI should be used in drug discovery or development, at least with today’s tools and incentives.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn.

If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes.

Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Sagi Sigali, Father and Founder of Rafa’s Moonshot – a non-profit dedicated to Landing a Cure for STXBP1. Sagi and I discuss how Rafa’s Moonshot is turning a rare genetic disorder (STXBP1) into an investable, de‑risked therapeutic opportunity. Sagi explains how his tech/entrepreneur background shapes a for‑profit mindset around fundraising, biopharma partnerships, and making rare disease indications attractive to industry. They cover building a global network, leveraging grants and consortia, working with academia/CROs, and planning the flip from nonprofit to for‑profit. They also dig into industry “anti‑patterns,” including copy‑paste development strategies, and explore a strategy to start from the drug label and work backwards. Sagi closes with his vision for a complete STXBP1 solution, a new CNS neurogenetic research center in Israel, and a stronger Israeli life sciences ecosystem.

Check out the main topics of discussion for this episode of the Life Sciences Today podcast:

Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.

Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business.

Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:

Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn.

If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes.

Thanks so much for listening!